Platelet and soluble glycoprotein VI - novel applications in diagnosis and therapy

Current Drug Targets

Volumn 12, Issue 12, 2011, Pages 1821-1830

  Bigalke, Boris ^a,b   Elvers, Margitta ^a   Schönberger, Tanja ^a   Gawaz, Meinrad ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Antithrombotic therapy; Biomarker; Plaque imaging; Platelet and soluble glycoprotein vi; Platelets

Indexed keywords

ANTITHROMBOCYTIC AGENT; APOLIPOPROTEIN E; B LYMPHOCYTE RECEPTOR; BIOLOGICAL MARKER; COLLAGEN BINDING PROTEIN; DIACYLGLYCEROL; GLYCOPROTEIN VI; INOSITOL 1,4,5 TRISPHOSPHATASE; LAMININ; PROTEIN KINASE C; REVACEPT; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ACUTE CORONARY SYNDROME; ARTICLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BERNARD SOULIER DISEASE; BRAIN ISCHEMIA; ELECTROCARDIOGRAM; GENE DELETION; HUMAN; HYPERTENSION; IN VIVO STUDY; MOLECULAR IMAGING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN FUNCTION; PROTEIN POLYMORPHISM; PROTEIN STRUCTURE; SINGLE DRUG DOSE;

ANIMALS; ANTIGENS, CD36; BIOLOGICAL MARKERS; BLOOD PLATELETS; FIBRINOLYTIC AGENTS; HUMANS; MOLECULAR IMAGING; NEOINTIMA; PLAQUE, ATHEROSCLEROTIC; PLATELET ACTIVATION; SOLUBILITY; THROMBOSIS;

EID: 80054065717     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945011797635867     Document Type: Article

References (84)

1. Savage B, Almus-Jacobs F, Ruggeri ZM. Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. Cell 1998; 94: 657-66.
2. Nieswandt B, Watson SP. Platelet-collagen interaction: is GPVI the central receptor? Blood 2003; 102: 449-61.
3. Sabri S, Jandrot-Perrus M, Bertoglio J, et al. Differential regulation of actin stress fiber assembly and proplatelet formation by alpha2beta1 integrin and GPVI in human megakaryocytes. Blood 2004; 104: 3117-25.
4. Clemetson KJ, Clemetson JM. Platelet collagen receptors. Thromb Haemost 2001; 86: 189-97.
5. Suzuki-Inoue K, Tulasne D, Shen Y. Association of Fyn and Lyn with the proline-rich domain of glycoprotein VI regulates intracellular signaling. J Biol Chem 2002; 277: 21561-6.
6. Ezumi Y, Shindoh K, Tsuji M, Takayama H. Physical and functional association of the Src family kinases Fyn and Lyn with the collagen receptor glycoprotein VI-Fc receptor gamma chain complex on human platelets. J Exp Med 1998; 188: 267-76.
7. Locke D, Liu C, Peng X, Chen H, Kahn ML. Fc Rgamma-independent signaling by the platelet collagen receptor glycoprotein VI. J Biol Chem 2003; 278: 15441-8.
8. Bori-Sanz T, Inoue KS, Berndt MC, Watson SP, Tulasne D. Delineation of the region in the glycoprotein VI tail required for association with the Fc receptor gamma-chain. J Biol Chem 2003; 278: 35914-22.
9. Watson SP, Auger JM, McCarty OJ, Pearce AC. GPVI and integrin alphaIIb beta3 signaling in platelets. J Thromb Haemost 2005; 3: 1752-62.
10. Pleines I, Elvers M, Strehl A, et al. Rac1 is essential for phospholipase C-gamma2 activation in platelets. Pflugers Arch 2009; 457: 1173-85.
11. Offermanns S. Activation of platelet function through G protein-coupled receptors. Circ Res 2006; 99: 1293-304.
12. Elvers M, Pozgaj R, Pleines I, et al. Platelet hyperreactivity and a prothrombotic phenotype in mice with a gain-of-function mutation in phospholipase Cgamma2. J Thromb Haemost 2010; 8(6): 1353-63.
13. Blake RA, Schieven GL, Watson SP. Collagen stimulates tyrosine phosphorylation of phospholipase C-gamma 2 but not phospholipase C-gamma 1 in human platelets. FEBS Lett. 1994; 353: 212-6.
14. Gibbins JM, Briddon S, Shutes A, et al. The p85 subunit of phosphatidylinositol 3-kinase associates with the Fc receptor gamma-chain and inker for activitor of T cells (LAT) in platelets stimulated by collagen and convulxin. J Biol Chem 1998; 273: 34437-43.
15. Watanabe N, Nakajima H, Suzuki H, et al. Functional phenotype of phosphoinositide 3-kinase p85alpha-null platelets characterized by an impaired response to GP VI stimulation. Blood 2003; 102: 541-8.
16. Kim S, Mangin P, Dangelmaier C, et al. Role of phosphoinositide 3-kinase beta in glycoprotein VI-mediated Akt activation in platelets. J Biol Chem 2009; 284: 33763-72.
17. Pasquet JM, Quek L, Pasquet S, et al. Evidence of a role for SHP-1 in platelet activation by the collagen receptor glycoprotein VI. J Biol Chem 2000; 275: 28526-31.
18. Jones KL, Hughan SC, Dopheide SM, Farndale RW, Jackson SP, Jackson DE. Platelet endothelial cell adhesion molecule-1 is a negative regulator of platelet-collagen interactions. Blood 2001; 98: 1456-63.
19. Cicmil M, Thomas JM, Leduc M, Bon C, Gibbins JM. Platelet endothelial cell adhesion molecule-1 signaling inhibits the activation of human platelets. Blood 2002; 99: 137-44.
20. Newman PJ, Newman DK. Signal transduction pathways mediated by PECAM-1: new roles for an old molecule in platelet and vascular cell biology. Arterioscler Thromb Vasc Biol 2003; 23: 953-64.
21. Rathore V, Stapleton MA, Hillery CA, et al. PECAM-1 negatively regulates GPIb/V/IX signaling in murine platelets. Blood 2003; 102: 3658-64.
22. Dhanjal TS, Ross EA, Auger JM, et al. Minimal regulation of platelet activity by PECAM-1. Platelets 2007; 18: 56-67.
23. Wee JL, Jackson DE. The Ig-ITIM superfamily member PECAM-1 regulates the outside-in signaling properties of integrin alpha(IIb)beta3 in platelets. Blood 2005; 106: 3816-23.
24. Arthur JF, Dunkley S, Andrews RK. Platelet glycoprotein VI-related clinical defects. Br J Haematol 2007; 139: 363-72.
25. Dumont B, Lasne D, Rothschild C, et al. Absence of collagen-induced platelet activation caused by compound heterozygous GPVI mutations. Blood 2009; 114: 1900-3.
26. Moroi M, Jung SM, Okuma M, et al. A patient with platelets deficient in glycoprotein VI that lack both collagen-inducedaggregation and adhesion. J Clin Invest 1989; 84: 1440-1445.
27. Boylan B, Chen H, Rathore V, et al. Anti-GPVI-associated ITP: an acquired platelet disorder caused by autoantibody-mediated clearance of the PVI/FcRgamma-chain complex from the human platelet surface. Blood 2004; 104: 1350-5.
28. Akiyama M, Kashiwagi H, Todo K, et al. Presence of platelet-associated anti-glycoprotein (GP)VI autoantibodies and restoration of GPVI expression in patients with GPVI deficiency. J Thromb Haemost 2009; 7: 1373-83.
29. Nieswandt B, Schulte V, Bergmeier W, et al. Long-term antithrombotic protection by in vivo depletion of platelet glycoprotein VI in mice. J Exp Med 2001; 193: 459-69.
30. Kato K, Kanaji T, Russell S, et al. The contribution of glycoprotein VI to stable platelet adhesion and thrombus formation illustrated by targeted gene deletion. Blood 2003; 102: 1701-7.
31. Konstantinides S, Ware J, Marchese P, Almus-Jacobs F, Loskutoff DJ, Ruggeri ZM. Distinct antithrombotic consequences of platelet glycoprotein balpha and VI deficiency in a mouse model of arterial thrombosis. J Thromb Haemost 2006; 4: 2014-21.
32. Lockyer S, Okuyama K, Begum S, et al. GPVI-deficient mice lack collagen responses and are protected against experimentally induced pulmonary thromboembolism. Thromb Res 2006; 118: 371-80.
33. Cheli Y, Jensen D, Marchese P, et al. The Modifier of hemostasis (Mh) locus on chromosome 4 controls in vivo hemostasis of Gp6-/- mice. Blood 2008; 111: 1266-73.
34. Gardiner EE, Arthur JF, Kahn ML, Berndt MC, Andrews RK. Regulation of platelet membrane levels of glycoprotein VI by a platelet-derived metalloproteinase. Blood 2004; 104: 3611-7.
35. Nagano S, Huang X, Moir RD, Payton SM, Tanzi RE, Bush AI. Peroxidase activity of cyclooxygenase-2 (COX-2) cross-links beta-amyloid (Abeta) and generates Abeta-COX-2 hetero-oligomers that are increased in Alzheimer's disease. J Biol Chem 2004; 279: 14673-8.
36. Rabie T, Varga-Szabo D, Bender M, et al. Diverging signaling events control the pathway of GPVI down-regulation in vivo. Blood 2007; 110: 529-35.
37. Gardiner EE, Karunakaran D, Shen Y, Arthur JF, Andrews RK, Berndt MC. Controlled shedding of platelet glycoprotein (GP)VI and GPIb-IX-V by ADAM family metalloproteinases. J Thromb Haemost 2007; 5: 1530-7.
38. Wijeyewickrema LC, Gardiner EE, Gladigau EL, Berndt MC, Andrews RK. Nerve growth factor inhibits metalloproteinase- disintegrins and blocks ectodomain shedding of platelet glycoprotein VI. J Biol Chem 2010; 285: 11793-9.
39. Laske C, Leyhe T, Stransky E, et al. Association of platelet-derived soluble glycoprotein VI in plasma with Alzheimer's disease. J Psychiatr Res 2008; 42: 746-51.
40. Cabeza N, Li Z, Schulz C, et al. Surface Expression of Collagen Receptor Fc Receptor γ/Glycoprotein VI Is Enhanced on Platelets in Type 2 Diabetes and Mediates Release of CD40 Ligand and Activation of Endothelial Cells. Diabetes 2004; 53: 2117-2121.
41. Clemetson KJ, McGregor JL, James E, et al. Characterization of the platelet membrane glycoprotein abnormalities in Bernard-Soulier syndrome and comparison with normal by surface-labeling techniques and high-resolution two-dimensional gel electrophoresis. J Clin Invest 1982; 70: 304-11.
42. Nieswandt B, Bergmeier W, Schulte V, Rackebrandt K, Gessner JE, Zirngibl H. Expression and function of the mouse collagen receptor glycoprotein VI is strictly dependent on its association with the FcRgamma chain. J Biol Chem 2000; 275: 23998-4002.
43. Massberg S, Gawaz M, Grüner S, et al. A crucial role of glycoprotein VI for platelet recruitment to the injured arterial wall in vivo. J Exp Med 2003; 197: 41-9.
44. Gawaz M. Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium. Cardiovasc Res 2004; 61: 498-511.
45. Gawaz M, Konrad I, Hauser AI, et al. Non-invasive imaging of glycoprotein VI binding to injured arterial lesions. Thromb Haemost 2005; 93: 910-3.
46. Ollikainen E, Mikkelsson J, Perola M, Penttilä A, Karhunen PJ. Platelet membrane collagen receptor glycoprotein VI polymorphism is associated with coronary thrombosis and fatal myocardial infarction in middle-aged men. Atherosclerosis 2004; 176: 95-9.
47. Heeschen C, Dimmeler S, Hamm CW, et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003; 348: 1104-11.
48. Kragelund C, Grønning B, Køber L, Hildebrandt P, Steffensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 2005; 352: 666-75.
49. Sabatine MS, Morrow DA, de Lemos JA, et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 2002; 105: 1760-3.
50. [50] Samaha FF, Hibbard C, Sacks J, et al. Density of platelet collagen receptors glycoprotein VI and alpha2beta1 and prior myocardial infarction in human subjects, a pilot study. Med Sci Monit 2005; 11: CR224-229.
51. Bigalke B, Lindemann S, Ehlers R, et al. Expression of platelet collagen receptor glycoprotein VI is associated with acute coronary syndrome. Eur Heart J 2006; 27: 2165-9.
52. Bigalke B, Geisler T, Stellos K, et al. Platelet Collagen Receptor Glycoprotein VI as a Possible Novel Indicator for the Acute Coronary Syndrome. Am Heart J 2008; 156: 193-200.
53. Bigalke B, Stellos K, Geisler T, et al. Expression of platelet glycoprotein VI is associated with transient ischemic attack and stroke. Eur J Neurol 2010; 17: 111-7.
54. Bigalke B, Stellos K, Weig HJ, et al. Regulation of platelet glycoprotein VI (GPVI) surface expression and of soluble GPVI in patients with atrial fibrillation (AF) and acute coronary syndrome (ACS). Basic Res Cardiol 2009; 104: 352-7.
55. Bigalke B, Stellos K, Stakos D, et al. Influence of platelet count on the expression of platelet collagen receptor glycoprotein VI (GPVI) in patients with acute coronary syndrome. Thromb Haemost 2009; 101: 911-5.
56. Watkins NA, O'Connor MN, Rankin A, et al. Definition of novel GP6 polymorphisms and major difference in haplotype frequencies between populations by a combination of in-depth exon resequencing and genotyping with tag single nucleotide polymorphisms. J Thromb Haemost 2006; 4: 1197-205.
57. Nurden P, Tandon N, Takizawa H, et al. An acquired inhibitor to the GPVI platelet collagen receptor in a patient with lupus nephritis. J Thromb Haemost 2009; 7: 1541-9.
58. Bigalke B, Stellos K, Geisler T, et al. Glycoprotein VI for diagnosis of acute coronary syndrome when ECG is ambiguous. Int J Cardiol 2011; 149; 164-8.
59. Bigalke B, Haap M, Stellos K, et al. Platelet glycoprotein VI (GPVI) for early identification of acute coronary syndrome in patients with chest pain. Thromb Res 2010; 125: e184-9.
60. Bigalke B, Stellos K, Geisler T, Lindemann S, May AE, Gawaz M. Glycoprotein VI as a prognostic biomarker for cardiovascular death in patients with symptomatic coronary artery disease. Clin Res Cardiol 2010; 99: 227-233.
61. Al-Tamimi M, Mu FT, Moroi M, et al. Measuring soluble platelet glycoprotein VI in human plasma by ELISA. Platelets 2009; 20: 143-149.
62. Matter CM, Stuber M, Nahrendorf M. Imaging of the unstable plaque: how far have we got? Eur Heart J 2009; 30: 2566-2574.
63. Myerburg RJ, Interian A, Jr., Mitrani RM, Kessler KM, Castellanos A. Frequency of sudden cardiac death and profiles of risk. Am J Cardiol 1997; 80: 10F-9F.
64. Silvera SS, Aidi HE, Rudd JH, et al. Multimodality imaging of atherosclerotic plaque activity and composition using FDG- PET/CT and MRI in carotid and femoral arteries. Atherosclerosis 2009; 207: 139-143.
65. Vallabhajosula S, Fuster V. Atherosclerosis: imaging techniques and the evolving role of nuclear medicine. J Nucl Med 1997; 38: 1788-1796.
66. Sinzinger H, Granegger S. Radionuclide vascular imaging and characterization of human metabolic endothelial surface lining. Q J Nucl Med Mol Imaging 2006; 50: 226-35.
67. von zur Muhlen C, von Elverfeldt D, Moeller JA, et al. Magneti resonance imaging contrast agent targeted toward activated platelets allows in vivo detection of thrombosis and monitoring of thrombolysis. Circulation 2008; 118: 258-267.
68. Kwee RM, van Osternbrugge RJ, Hofstra L, et al. Identifying vulnerable carotid plaques by noninvasive imaging. Neurology 2008; 70: 2401-9.
69. Gawaz M, Konrad I, Hauser AI, et al. Non-invasive imaging of glycoprotein VI binding to injured arterial lesions. Thromb Haemost 2005; 93: 910-3.
70. Langer H, Schönberger T, Bigalke B, Gawaz M. Where is the trace? Molecular imaging of vulnerable atherosclerotic plaques. Semin Thromb Hemost 2007; 33: 151-8.
71. Schulz C, Penz S, Hoffmann C, et al. Platelet GPVI binds to collagenous structures in the core region of human atheromatous plaque and is critical for atheroprogression in vivo. Basic Res Cardiol 2008; 103: 356-367.
72. Massberg S, Konrad I, Bültmann A, et al. Soluble glycoprotein VI dimer inhibits platelet adhesion and aggregation to the injured vessel wall in vivo. FASEB J 2004; 18: 397-9.
73. Bültmann A, Herdeg C, Li Z, et al. Local delivery of soluble platelet collagen receptor glycoprotein VI inhibits thrombus formation in vivo. Thromb Haemost 2006; 95: 763-6.
74. Hamilos MI, Ostojic M, Beleslin B, et al. Differential Effects of Drug-Eluting Stents on Local Endothelium-Dependent Coronary Vasomotion. J Am Coll Cardiol 2008; 51: 2123-9.
75. Cosemans JM, Kuijpers MJ, Lecut C, et al. Contribution of platelet glycoprotein VI to the thrombogenic effect of collagens in fibrous atherosclerotic lesions. Atherosclerosis 2005; 181: 19-27.
76. Penz S, Reininger AJ, Brandl R, et al. Human atheromatous plaques stimulate thrombus formation by activating platelet glycoprotein VI. FASEB J 2005; 19: 898-909.
77. Boylan B, Chen H, Rathore V, et al. Anti-GPVI-associated ITP: an acquired platelet disorder caused by autoantibody-mediated clearance of the GPVI/FcRgamma-chain complex from the human platelet surface. Blood 2004; 104: 1350-5.
78. Grüner S, Prostredna M, Koch M, et al. Relative antithrombotic effect of soluble GPVI dimer compared with anti-GPVI antibodies in mice. Blood 2005; 105: 1492-9.
79. Kleinschnitz C, Pozgajova M, Pham M, Bendszus M, Nieswandt B, Stoll G. Targeting platelets in acute experimental stroke: impact of glycoprotein Ib, VI, and IIb/IIIa blockade on infarct size, functional outcome, and intracranial bleeding. Circulation 2007; 115: 2323-2330.
80. Schönberger T, Siegel-Axel D, Bussl R, et al. The immunoadhesin glycoprotein VI-Fc regulates arterial remodelling after mechanical injury in ApoE-/- mice. Cardiovasc Res 2008; 80: 131-137.
81. Takayama H, Hosaka Y, Nakayama K, et al. A novel antiplatelet antibody therapy that induces cAMP-ependent endocytosis of the GPVI/Fc receptor gamma-chain complex. J Clin Invest 2008; 118: 1785-95.
82. Jain S, Russell S, Ware J. Platelet glycoprotein VI facilitates experimental lung metastasis in syngenic mouse models. J Thromb Haemost 2009; 7: 1713-7.
83. Langer HF, von der Ruhr JW, Daub K, et al. Capture of endothelial progenitor cells by a bispecific protein/monoclonal antibody molecule induces reendothelialization of vascular lesions. J Mol Med 2010; 88: 687-699.
84. Moroi M, Jung SM. Platelet glycoprotein VI: its structure and function. Thromb Res 2004; 114: 221-233.